Cosyntropin Trial Update: Study on Adrenal Insufficiency in RA Now Recruiting

A clinical trial involving cosyntropin was updated on October 8, 2026, with a status of recruiting. The study, registered as NCT07866326, is titled "Prevalence of Adrenal Insufficiency and Associated Factors in Rheumatoid Arthritis Patients Using Low-dose Corticosteroids." No phase was specified for this trial in the available record. The trial is currently open for participant enrollment according to its ClinicalTrials.gov listing. Cosyntropin remains an approved compound used in this research context. No results or outcomes have been posted for this study at this time. The trial's stated focus is examining adrenal insufficiency prevalence and its associated factors among rheumatoid arthritis patients who are using low-dose corticosteroids. As this is a recruiting study, enrollment and data collection are understood to be ongoing processes. No efficacy or safety findings have been reported as part of this update. Readers interested in further details can consult the official trial registration for additional information on eligibility and study design. For more background on cosyntropin as a compound, readers can refer to the overview page for additional context.